Impel NeuroPharma, Inc.
News
Impel Pharmaceuticals Third Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag
Simply Wall St Impel Pharmaceuticals ( NASDAQ:IMPL ) Third Quarter 2023 Results Key Financial Results Revenue: US$5.02m (up 63% from...\n more…
Impel Pharmaceuticals Inc.'s (NASDAQ:IMPL) Profit Outlook
Simply Wall St Impel Pharmaceuticals Inc. ( NASDAQ:IMPL ) is possibly approaching a major achievement in its business, so we would...\n more…
DCF Advisers LLC Sells 79,543 Shares of Impel Pharmaceuticals Inc. (NASDAQ:IMPL)
Ticker Report DCF Advisers LLC reduced its holdings in Impel Pharmaceuticals Inc. (NASDAQ:IMPL Free Report) by 20.8% in the second quarter, according to the company in its most recent Form 13F filing with...\n more…
Adrian Adams steps down as CEO of Seattle's Impel Pharmaceuticals
BizJournals.com - Nat'l Business News The publicly traded biopharmaceutical company also faces delisting from the Nasdaq.\n more…
Impel Pharmaceuticals Announces Exploration of Strategic Alternatives
Globe Newswire SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL) ( Impel or the Company ), a commercial-stage biopharmaceutical company with a mission to develop...\n more…